Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head

Takeda's ALK inhibitor meets primary endpoint in interim analysis from critical first-line lung cancer head-to-head study, helping validate Ariad acquisition, but will be a relative class latecomer to the setting.  

Cancer cells on scientific background.3d illustration
PROMISING RESULTS FOR BRIGATINIB IN FIRST-LINE NSCLC • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.'s oral anaplastic lymphoma kinase (ALK) inhibitor brigatinib has shown progression-free survival (PFS) benefits over close rival crizotinib in the first interim analysis from an ongoing head-to-head trial in the commercially important first-line lung cancer setting.

While the Japanese firm did not disclose details of the top-line findings, it said the first pre-specified interim analysis from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.